# Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

> **NCT00618657** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 127 (actual)

## Conditions studied

- Breast Cancer
- HER2-negative Breast Cancer
- HER2-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **DRUG:** bevacizumab
- **DRUG:** trastuzumab
- **PROCEDURE:** magnetic resonance imaging
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00618657
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2021-07
- **Final completion:** 2021-07
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00618657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00618657, "Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00618657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*